Cargando…

DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis

BACKGROUND: Thalamic volume loss is a key marker of neurodegeneration in multiple sclerosis (MS). T2-FLAIR MRI is a common denominator in clinical routine MS imaging, but current methods for thalamic volumetry are not applicable to it. OBJECTIVE: To develop and validate a robust algorithm to measure...

Descripción completa

Detalles Bibliográficos
Autores principales: Dwyer, Michael, Lyman, Cassondra, Ferrari, Hannah, Bergsland, Niels, Fuchs, Tom A., Jakimovski, Dejan, Schweser, Ferdinand, Weinstock-Guttmann, Bianca, Benedict, Ralph H.B., Riolo, Jon, Silva, Diego, Zivadinov, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080069/
https://www.ncbi.nlm.nih.gov/pubmed/33872992
http://dx.doi.org/10.1016/j.nicl.2021.102652
_version_ 1783685352416870400
author Dwyer, Michael
Lyman, Cassondra
Ferrari, Hannah
Bergsland, Niels
Fuchs, Tom A.
Jakimovski, Dejan
Schweser, Ferdinand
Weinstock-Guttmann, Bianca
Benedict, Ralph H.B.
Riolo, Jon
Silva, Diego
Zivadinov, Robert
author_facet Dwyer, Michael
Lyman, Cassondra
Ferrari, Hannah
Bergsland, Niels
Fuchs, Tom A.
Jakimovski, Dejan
Schweser, Ferdinand
Weinstock-Guttmann, Bianca
Benedict, Ralph H.B.
Riolo, Jon
Silva, Diego
Zivadinov, Robert
author_sort Dwyer, Michael
collection PubMed
description BACKGROUND: Thalamic volume loss is a key marker of neurodegeneration in multiple sclerosis (MS). T2-FLAIR MRI is a common denominator in clinical routine MS imaging, but current methods for thalamic volumetry are not applicable to it. OBJECTIVE: To develop and validate a robust algorithm to measure thalamic volume using clinical routine T2-FLAIR MRI. METHODS: A dual-stage deep learning approach based on 3D U-net (DeepGRAI – Deep Gray Rating via Artificial Intelligence) was created and trained/validated/tested on 4,590 MRI exams (4288 2D-FLAIR, 302 3D-FLAIR) from 59 centers (80/10/10 train/validation/test split). As training/test targets, FIRST was used to generate thalamic masks from 3D T1 images. Masks were reviewed, corrected, and aligned into T2-FLAIR space. Additional validation was performed to assess inter-scanner reliability (177 subjects at 1.5 T and 3 T within one week) and scan-rescan-reliability (5 subjects scanned, repositioned, and then re-scanned). A longitudinal dataset including assessment of disability and cognition was used to evaluate the predictive value of the approach. RESULTS: DeepGRAI automatically quantified thalamic volume in approximately 7 s per case, and has been made publicly available. Accuracy on T2-FLAIR relative to 3D T1 FIRST was 99.4% (r = 0.94, p < 0.001,TPR = 93.0%, FPR = 0.3%). Inter-scanner error was 3.21%. Scan-rescan error with repositioning was 0.43%. DeepGRAI-derived thalamic volume was associated with disability (r = -0.427,p < 0.001) and cognition (r = -0.537,p < 0.001), and was a significant predictor of longitudinal cognitive decline (R(2) = 0.081, p = 0.024; comparatively, FIRST-derived volume was R(2) = 0.080, p = 0.025). CONCLUSIONS: DeepGRAI provides fast, reliable, and clinically relevant thalamic volume measurement on multicenter clinical-quality T2-FLAIR images. This indicates potential for real-world thalamic volumetry, as well as quantification on legacy datasets without 3D T1 imaging.
format Online
Article
Text
id pubmed-8080069
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80800692021-05-03 DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis Dwyer, Michael Lyman, Cassondra Ferrari, Hannah Bergsland, Niels Fuchs, Tom A. Jakimovski, Dejan Schweser, Ferdinand Weinstock-Guttmann, Bianca Benedict, Ralph H.B. Riolo, Jon Silva, Diego Zivadinov, Robert Neuroimage Clin Regular Article BACKGROUND: Thalamic volume loss is a key marker of neurodegeneration in multiple sclerosis (MS). T2-FLAIR MRI is a common denominator in clinical routine MS imaging, but current methods for thalamic volumetry are not applicable to it. OBJECTIVE: To develop and validate a robust algorithm to measure thalamic volume using clinical routine T2-FLAIR MRI. METHODS: A dual-stage deep learning approach based on 3D U-net (DeepGRAI – Deep Gray Rating via Artificial Intelligence) was created and trained/validated/tested on 4,590 MRI exams (4288 2D-FLAIR, 302 3D-FLAIR) from 59 centers (80/10/10 train/validation/test split). As training/test targets, FIRST was used to generate thalamic masks from 3D T1 images. Masks were reviewed, corrected, and aligned into T2-FLAIR space. Additional validation was performed to assess inter-scanner reliability (177 subjects at 1.5 T and 3 T within one week) and scan-rescan-reliability (5 subjects scanned, repositioned, and then re-scanned). A longitudinal dataset including assessment of disability and cognition was used to evaluate the predictive value of the approach. RESULTS: DeepGRAI automatically quantified thalamic volume in approximately 7 s per case, and has been made publicly available. Accuracy on T2-FLAIR relative to 3D T1 FIRST was 99.4% (r = 0.94, p < 0.001,TPR = 93.0%, FPR = 0.3%). Inter-scanner error was 3.21%. Scan-rescan error with repositioning was 0.43%. DeepGRAI-derived thalamic volume was associated with disability (r = -0.427,p < 0.001) and cognition (r = -0.537,p < 0.001), and was a significant predictor of longitudinal cognitive decline (R(2) = 0.081, p = 0.024; comparatively, FIRST-derived volume was R(2) = 0.080, p = 0.025). CONCLUSIONS: DeepGRAI provides fast, reliable, and clinically relevant thalamic volume measurement on multicenter clinical-quality T2-FLAIR images. This indicates potential for real-world thalamic volumetry, as well as quantification on legacy datasets without 3D T1 imaging. Elsevier 2021-03-29 /pmc/articles/PMC8080069/ /pubmed/33872992 http://dx.doi.org/10.1016/j.nicl.2021.102652 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Regular Article
Dwyer, Michael
Lyman, Cassondra
Ferrari, Hannah
Bergsland, Niels
Fuchs, Tom A.
Jakimovski, Dejan
Schweser, Ferdinand
Weinstock-Guttmann, Bianca
Benedict, Ralph H.B.
Riolo, Jon
Silva, Diego
Zivadinov, Robert
DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis
title DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis
title_full DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis
title_fullStr DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis
title_full_unstemmed DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis
title_short DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis
title_sort deepgrai (deep gray rating via artificial intelligence): fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality t2-flair mri in multiple sclerosis
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080069/
https://www.ncbi.nlm.nih.gov/pubmed/33872992
http://dx.doi.org/10.1016/j.nicl.2021.102652
work_keys_str_mv AT dwyermichael deepgraideepgrayratingviaartificialintelligencefastfeasibleandclinicallyrelevantthalamicatrophymeasurementonclinicalqualityt2flairmriinmultiplesclerosis
AT lymancassondra deepgraideepgrayratingviaartificialintelligencefastfeasibleandclinicallyrelevantthalamicatrophymeasurementonclinicalqualityt2flairmriinmultiplesclerosis
AT ferrarihannah deepgraideepgrayratingviaartificialintelligencefastfeasibleandclinicallyrelevantthalamicatrophymeasurementonclinicalqualityt2flairmriinmultiplesclerosis
AT bergslandniels deepgraideepgrayratingviaartificialintelligencefastfeasibleandclinicallyrelevantthalamicatrophymeasurementonclinicalqualityt2flairmriinmultiplesclerosis
AT fuchstoma deepgraideepgrayratingviaartificialintelligencefastfeasibleandclinicallyrelevantthalamicatrophymeasurementonclinicalqualityt2flairmriinmultiplesclerosis
AT jakimovskidejan deepgraideepgrayratingviaartificialintelligencefastfeasibleandclinicallyrelevantthalamicatrophymeasurementonclinicalqualityt2flairmriinmultiplesclerosis
AT schweserferdinand deepgraideepgrayratingviaartificialintelligencefastfeasibleandclinicallyrelevantthalamicatrophymeasurementonclinicalqualityt2flairmriinmultiplesclerosis
AT weinstockguttmannbianca deepgraideepgrayratingviaartificialintelligencefastfeasibleandclinicallyrelevantthalamicatrophymeasurementonclinicalqualityt2flairmriinmultiplesclerosis
AT benedictralphhb deepgraideepgrayratingviaartificialintelligencefastfeasibleandclinicallyrelevantthalamicatrophymeasurementonclinicalqualityt2flairmriinmultiplesclerosis
AT riolojon deepgraideepgrayratingviaartificialintelligencefastfeasibleandclinicallyrelevantthalamicatrophymeasurementonclinicalqualityt2flairmriinmultiplesclerosis
AT silvadiego deepgraideepgrayratingviaartificialintelligencefastfeasibleandclinicallyrelevantthalamicatrophymeasurementonclinicalqualityt2flairmriinmultiplesclerosis
AT zivadinovrobert deepgraideepgrayratingviaartificialintelligencefastfeasibleandclinicallyrelevantthalamicatrophymeasurementonclinicalqualityt2flairmriinmultiplesclerosis